Review of Promising Off-Label Use of Deucravacitinib

Deucravacitinib, a selective TYK2 inhibitor, shows promise for off-label use in various immune-mediated diseases beyond its approved use for psoriasis. It has demonstrated potential benefits in conditions like alopecia areata, systemic lupus erythematosus, psoriatic arthritis, and more, due to its ability to suppress cytokine signaling. Case reports and clinical trials indicate significant improvements in symptoms and hair regrowth in conditions like discoid lupus erythematosus and alopecia areata. While its safety profile is favorable, further large-scale studies are needed to confirm its efficacy and expand its therapeutic applications.